Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

JoeTheMiner Dec. 5 at 12:33 AM

$GUTS $SLS Bought again today at 1.9 This is a candidate for takeover for $PFE $NVO or $NVS I hope for a $5BILLION takeover. It is the perfect fit for drug like ozempic. Work in tandem Why peter Thiel is shareholder? 🤫🧐

1 · Reply

JoeTheMiner Dec. 4 at 11:42 PM

$FLYE $GUTS $KZIA $FRGE Patients should look solutions to $GUTS Patients are being warned to stop using some glucose monitors made by Abbott Diabetes Care after the company found malfunctioning sensors may be linked to hundreds of adverse events and several deaths, the Food and Drug Administration said Tuesday. https://www.cbsnews.com/news/abbott-diabetes-care-glucose-monitor-freestyle-libre-3-plus-sensor-recall/

0 · Reply

JoeTheMiner Dec. 4 at 10:33 PM

$GUTS we are legion, We will see this raise to 8$ We will see have 50000 watchers Fasten your seat belt Hello $PFE , We welcome a takeover at 8$ GUTS has +30 patents

1 · Reply

__AvengerTrader Dec. 4 at 10:05 PM

What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. watching $FLYE $GUTS $KZIA $FRGE ,,

0 · Reply

jacksparo Dec. 4 at 7:32 PM

$GUTS $ADCT $BULL $ESPR I am looking into new trade opportunities Let’s us see what we have in 2026/27 Journey 📈📈✅📈📈✅! I will share my trade ideas via the email / Telegram as usual 📈📈📈!

3 · Reply

BENNYST Dec. 4 at 6:19 PM

$ALT or $GUTS who is better stock ?

5 · Reply

SmackMyBidUp Dec. 4 at 6:04 PM

$GUTS $SLS "Phase 3 results may have leaked out" I didn't used to think @Juhanialainen was one of the shameless pumper crowd, but this comment causes me to review that assessment

1 · Reply

JoeTheMiner Dec. 4 at 5:56 PM

$GUTS $SLS @BioRich @Juhanialainen On Twitter: https://x.com/Vulpescap/status/1996635666206413112?t=DA-fpsifbBTUL9WBWZ86FA&s=19

1 · Reply

Babilon1210 Dec. 4 at 5:49 PM

$GUTS $SLS will take SLS profits into GUTS

1 · Reply

JoeTheMiner Dec. 4 at 5:41 PM

$GUTS $SLS Thanks @Juhanialainen $GUTS HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8.X price target.

1 · Reply

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Dec 1, 2025, 7:00 AM EST - 3 days ago

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 8:21 PM EST - 22 days ago

Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 22 days ago

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Oct 7, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Oct 1, 2025, 5:14 AM EDT - 2 months ago

Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang

Sep 26, 2025, 11:07 AM EDT - 2 months ago

Fractyl Health, Inc. - Special Call

Sep 26, 2025, 7:41 AM EDT - 2 months ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 2 months ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 5, 2025, 6:05 PM EDT - 3 months ago

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 4 months ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 4 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 4 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 4 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 5 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 5 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 5 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 7 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 7 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 7 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 7 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 7 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 7 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 7 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 9 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 9 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 10 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 10 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 1 year ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 1 year ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

JoeTheMiner Dec. 5 at 12:33 AM

1 · Reply

JoeTheMiner Dec. 4 at 11:42 PM

0 · Reply

JoeTheMiner Dec. 4 at 10:33 PM

$GUTS we are legion, We will see this raise to 8$ We will see have 50000 watchers Fasten your seat belt Hello $PFE , We welcome a takeover at 8$ GUTS has +30 patents

1 · Reply

__AvengerTrader Dec. 4 at 10:05 PM

0 · Reply

jacksparo Dec. 4 at 7:32 PM

3 · Reply

BENNYST Dec. 4 at 6:19 PM

$ALT or $GUTS who is better stock ?

5 · Reply

SmackMyBidUp Dec. 4 at 6:04 PM

$GUTS $SLS "Phase 3 results may have leaked out" I didn't used to think @Juhanialainen was one of the shameless pumper crowd, but this comment causes me to review that assessment

1 · Reply

JoeTheMiner Dec. 4 at 5:56 PM

$GUTS $SLS @BioRich @Juhanialainen On Twitter: https://x.com/Vulpescap/status/1996635666206413112?t=DA-fpsifbBTUL9WBWZ86FA&s=19

1 · Reply

Babilon1210 Dec. 4 at 5:49 PM

$GUTS $SLS will take SLS profits into GUTS

1 · Reply

JoeTheMiner Dec. 4 at 5:41 PM

$GUTS $SLS Thanks @Juhanialainen $GUTS HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8.X price target.

1 · Reply

SannieVerraderlijk Dec. 4 at 5:27 PM

$GUTS 2! Still so undervalued here, will run up into data, maybe 5 before readout

0 · Reply

Juhanialainen Dec. 4 at 4:55 PM

$GUTS I’m in since yesterday. Seems like a great time. In the meantime, get in $SLS too. Phase 3 results may have leaked out.

0 · Reply

JoeTheMiner Dec. 4 at 4:20 PM

$ALT $GUTS $TERN Still can't understand why $GUTS has less than 1300 watchers. People will come here when it's $8.X ?

3 · Reply

StockBraker Dec. 4 at 2:02 PM

$GUTS @BostonNorth Put this one on your radar.

0 · Reply

TaoHaus Dec. 4 at 12:51 PM

$GUTS just noticed this has jumped.🔥🫶🏼

0 · Reply

JoeTheMiner Dec. 4 at 12:02 PM

$XBI $CAPR $MIST $GUTS good morning beautiful people ☀️ Let's make money today

0 · Reply

Waleedmusa Dec. 4 at 1:19 AM

$GUTS

1 · Reply

JoeTheMiner Dec. 3 at 10:48 PM

$XBI $CAPR $MIST $GUTS Target $8.X

1 · Reply

BioRich Dec. 3 at 7:11 PM

$XBI Good Lord folks. My $CAPR hit today. $GUTS is hitting now (the Holy Grail of Weight Loss Retention following GLP-1 Discontinuation) and $MIST looks like it will get FDA approval in the next few days. Exciting times folks. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

1 · Reply

JoeTheMiner Dec. 3 at 7:11 PM

$GUTS let's go $5

0 · Reply

APman Dec. 3 at 7:07 PM

$GUTS The charts say the insiders bought before the public knew the data.

0 · Reply

pietroq Dec. 3 at 7:00 PM

$ALT we’re having very great news on $GUTS! Listen the conference yall that they’re having rn

1 · Reply

Market Cap	252.16M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-9.68

Volume	3,808,500
Avg Vol	4,437,078
Day's Range	N/A - N/A
Shares Out	137.04M
Stochastic %K	98%
Beta	1.96
Analysts	Strong Sell
Price Target	$7.44